Synthetic Biologics, Inc. (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: November 21, 2014
Pages: 38
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S2595A53AACEN
Leaflet:

Download PDF Leaflet

Synthetic Biologics, Inc. (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Synthetic Biologics, Inc. (Synthetic Biologics), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company. It undertakes the development of anti-infective biologics and drug candidates targeting infections and disease specific pathogens. The company also develops synthetic biologic candidates including a series of monoclonal antibodies for the treatment of serious infectious diseases. Its pipeline product portfolio includes Trimesta, SYN-004, SYN-010, SYN-005, SYN-001, and SYN-007. Synthetic Biologics products find application in the treatment of relapsing-remitting multiple sclerosis, cognitive dysfunction in multiple sclerosis, C. difficile infection prevention, pertussis, acinetobacter infection and irritable bowel syndrome. It has collaborations with academic and pharmaceutical companies such as Cedars-Sinai Medical Center, Intrexon Corporation and The University of Texas at Austin to develop its products. Synthetic Biologics is headquartered in Rockville, Maryland, United States.

Synthetic Biologics, Inc. (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Purchase
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR
Adeona Pharma Acquires Oral dnaJP1 From Undisclosed Company
Partnerships
Synthetic Biologics Enters Into Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases
Adeona Pharma Enters Into Co-Development Agreement With Intrexon
Adeona Pharma Enters Into Co-Development Agreement With Meda
Adeona Pharma Enters Into Research Agreement With National Neurovision Research Institute
Licensing Agreements
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center
Pipex Therapeutics Amends Licensing Agreement With University of Michigan
Equity Offering
Synthetic Biologics to Raise USD20.7 Million in Private Placement of Units
Synthetic Biologics Completes Public Offering Of Shares For US$13.2 Million
Synthetic Biologics Completes Private Placement Of Common Stock For US$11 Million
Adeona Pharma Completes Private Placement Of Shares For US$3.5 Million
Adeona Pharma Completes Registered Direct Offering For US$4 Million
Adeona Pharma Completes Private Placement Of US$1 Million
Acquisition
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics
Adeona Pharma Completes Acquisition Of Hartlab
Synthetic Biologics, Inc. - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Key Facts, 2013
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Synthetic Biologics, Inc., Deals By Therapy Area, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR
Adeona Pharma Acquires Oral dnaJP1 From Undisclosed Company
Synthetic Biologics Enters Into Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases
Adeona Pharma Enters Into Co-Development Agreement With Intrexon
Adeona Pharma Enters Into Co-Development Agreement With Meda
Adeona Pharma Enters Into Research Agreement With National Neurovision Research Institute
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center
Pipex Therapeutics Amends Licensing Agreement With University of Michigan
Synthetic Biologics to Raise USD20.7 Million in Private Placement of Units
Synthetic Biologics Completes Public Offering Of Shares For US$13.2 Million
Synthetic Biologics Completes Private Placement Of Common Stock For US$11 Million
Adeona Pharma Completes Private Placement Of Shares For US$3.5 Million
Adeona Pharma Completes Registered Direct Offering For US$4 Million
Adeona Pharma Completes Private Placement Of US$1 Million
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics
Adeona Pharma Completes Acquisition Of Hartlab
Synthetic Biologics, Inc., Key Competitors
Synthetic Biologics, Inc., Key Employees
Synthetic Biologics, Inc., Other Locations
Synthetic Biologics, Inc., Subsidiaries

LIST OF FIGURES

Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Synthetic Biologics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Skip to top


Ask Your Question

Synthetic Biologics, Inc. (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: